Is JetBlue The Best Airline Stock?
Following a general trend of improvement among airline stocks, shares…
Sell
13
BRTX Quote, Financials, Valuation and Earnings
Last price:
$1.11
Seasonality move
:
-2.73%
Day range:
$1.08 - $1.15
52-week range:
$0.98 - $2.55
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
23.77x
P/B ratio:
4.45x
Volume:
24.9K
Avg. volume:
64.1K
1-year change:
-24.66%
Market cap:
$9.8M
Revenue:
$401K
EPS (TTM):
-$1.51
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
BRTX
BioRestorative Therapies, Inc.
|
$460K | -$0.38 | 246.42% | -48.05% | $13.00 |
|
ADPT
Adaptive Biotechnologies Corp.
|
$64.6M | -$0.14 | 24.92% | -21.12% | $19.86 |
|
AIM
AIM ImmunoTech
|
-- | -$0.09 | -23.08% | -53.85% | $4.50 |
|
CVM
CEL-SCI Corp.
|
-- | -- | -- | -- | $42.50 |
|
IGC
IGC Pharma, Inc.
|
$383K | -$0.02 | -7.04% | -11.5% | $3.88 |
|
TOI
The Oncology Institute, Inc.
|
$122.6M | -$0.10 | 39.41% | -52.63% | $6.50 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
BRTX
BioRestorative Therapies, Inc.
|
$1.10 | $13.00 | $9.8M | -- | $0.00 | 0% | 23.77x |
|
ADPT
Adaptive Biotechnologies Corp.
|
$15.42 | $19.86 | $2.4B | -- | $0.00 | 0% | 9.34x |
|
AIM
AIM ImmunoTech
|
$0.04 | $4.50 | $2.8M | -- | $0.00 | 0% | 13.27x |
|
CVM
CEL-SCI Corp.
|
$6.48 | $42.50 | $19.7M | -- | $0.00 | 0% | -- |
|
IGC
IGC Pharma, Inc.
|
$0.33 | $3.88 | $30.5M | -- | $0.00 | 0% | 24.61x |
|
TOI
The Oncology Institute, Inc.
|
$3.50 | $6.50 | $344.3M | -- | $0.00 | 0% | 0.65x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
BRTX
BioRestorative Therapies, Inc.
|
-- | 0.614 | -- | 1.31x |
|
ADPT
Adaptive Biotechnologies Corp.
|
51.1% | 3.094 | 9.36% | 3.09x |
|
AIM
AIM ImmunoTech
|
48.41% | 0.745 | 17.25% | 0.71x |
|
CVM
CEL-SCI Corp.
|
58.65% | 1.679 | 143.38% | 0.32x |
|
IGC
IGC Pharma, Inc.
|
1.82% | 0.805 | 0.39% | 0.78x |
|
TOI
The Oncology Institute, Inc.
|
113.45% | -2.011 | 30.41% | 1.33x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
BRTX
BioRestorative Therapies, Inc.
|
-$51.4K | -$3.7M | -199.46% | -199.72% | -31432.2% | -$2.9M |
|
ADPT
Adaptive Biotechnologies Corp.
|
$72.6M | $10.3M | -18.96% | -39.8% | 10.95% | -$7.5M |
|
AIM
AIM ImmunoTech
|
$27K | -$4.5M | -219.06% | -256.33% | -9994.29% | -$3.3M |
|
CVM
CEL-SCI Corp.
|
-$959K | -$5.5M | -123.39% | -266.61% | -- | -$3.9M |
|
IGC
IGC Pharma, Inc.
|
-$6K | -$2.9M | -91.27% | -94.42% | -1517.8% | -$2.4M |
|
TOI
The Oncology Institute, Inc.
|
$17.2M | -$8.1M | -48.97% | -9486.64% | -5.9% | -$13.2M |
BioRestorative Therapies, Inc. vs. Competitors
-
Which has Higher Returns BRTX or ADPT?
Adaptive Biotechnologies Corp. has a net margin of -25748.31% compared to BioRestorative Therapies, Inc.'s net margin of 10.16%. BioRestorative Therapies, Inc.'s return on equity of -199.72% beat Adaptive Biotechnologies Corp.'s return on equity of -39.8%.
Company Gross Margin Earnings Per Share Invested Capital BRTXBioRestorative Therapies, Inc.-435.59% -$0.33 $2.2M ADPTAdaptive Biotechnologies Corp.77.3% $0.06 $417.9M -
What do Analysts Say About BRTX or ADPT?
BioRestorative Therapies, Inc. has a consensus price target of $13.00, signalling upside risk potential of 1081.82%. On the other hand Adaptive Biotechnologies Corp. has an analysts' consensus of $19.86 which suggests that it could grow by 28.78%. Given that BioRestorative Therapies, Inc. has higher upside potential than Adaptive Biotechnologies Corp., analysts believe BioRestorative Therapies, Inc. is more attractive than Adaptive Biotechnologies Corp..
Company Buy Ratings Hold Ratings Sell Ratings BRTXBioRestorative Therapies, Inc.1 0 0 ADPTAdaptive Biotechnologies Corp.5 1 0 -
Is BRTX or ADPT More Risky?
BioRestorative Therapies, Inc. has a beta of 0.082, which suggesting that the stock is 91.819% less volatile than S&P 500. In comparison Adaptive Biotechnologies Corp. has a beta of 2.201, suggesting its more volatile than the S&P 500 by 120.134%.
-
Which is a Better Dividend Stock BRTX or ADPT?
BioRestorative Therapies, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Adaptive Biotechnologies Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioRestorative Therapies, Inc. pays -- of its earnings as a dividend. Adaptive Biotechnologies Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BRTX or ADPT?
BioRestorative Therapies, Inc. quarterly revenues are $11.8K, which are smaller than Adaptive Biotechnologies Corp. quarterly revenues of $94M. BioRestorative Therapies, Inc.'s net income of -$3M is lower than Adaptive Biotechnologies Corp.'s net income of $9.5M. Notably, BioRestorative Therapies, Inc.'s price-to-earnings ratio is -- while Adaptive Biotechnologies Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioRestorative Therapies, Inc. is 23.77x versus 9.34x for Adaptive Biotechnologies Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BRTXBioRestorative Therapies, Inc.23.77x -- $11.8K -$3M ADPTAdaptive Biotechnologies Corp.9.34x -- $94M $9.5M
-
Which has Higher Returns BRTX or AIM?
AIM ImmunoTech has a net margin of -25748.31% compared to BioRestorative Therapies, Inc.'s net margin of -10571.43%. BioRestorative Therapies, Inc.'s return on equity of -199.72% beat AIM ImmunoTech's return on equity of -256.33%.
Company Gross Margin Earnings Per Share Invested Capital BRTXBioRestorative Therapies, Inc.-435.59% -$0.33 $2.2M AIMAIM ImmunoTech77.14% -$0.06 $5.6M -
What do Analysts Say About BRTX or AIM?
BioRestorative Therapies, Inc. has a consensus price target of $13.00, signalling upside risk potential of 1081.82%. On the other hand AIM ImmunoTech has an analysts' consensus of $4.50 which suggests that it could grow by 11066.25%. Given that AIM ImmunoTech has higher upside potential than BioRestorative Therapies, Inc., analysts believe AIM ImmunoTech is more attractive than BioRestorative Therapies, Inc..
Company Buy Ratings Hold Ratings Sell Ratings BRTXBioRestorative Therapies, Inc.1 0 0 AIMAIM ImmunoTech1 0 0 -
Is BRTX or AIM More Risky?
BioRestorative Therapies, Inc. has a beta of 0.082, which suggesting that the stock is 91.819% less volatile than S&P 500. In comparison AIM ImmunoTech has a beta of 0.760, suggesting its less volatile than the S&P 500 by 23.953%.
-
Which is a Better Dividend Stock BRTX or AIM?
BioRestorative Therapies, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AIM ImmunoTech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioRestorative Therapies, Inc. pays -- of its earnings as a dividend. AIM ImmunoTech pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BRTX or AIM?
BioRestorative Therapies, Inc. quarterly revenues are $11.8K, which are smaller than AIM ImmunoTech quarterly revenues of $35K. BioRestorative Therapies, Inc.'s net income of -$3M is higher than AIM ImmunoTech's net income of -$3.7M. Notably, BioRestorative Therapies, Inc.'s price-to-earnings ratio is -- while AIM ImmunoTech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioRestorative Therapies, Inc. is 23.77x versus 13.27x for AIM ImmunoTech. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BRTXBioRestorative Therapies, Inc.23.77x -- $11.8K -$3M AIMAIM ImmunoTech13.27x -- $35K -$3.7M
-
Which has Higher Returns BRTX or CVM?
CEL-SCI Corp. has a net margin of -25748.31% compared to BioRestorative Therapies, Inc.'s net margin of --. BioRestorative Therapies, Inc.'s return on equity of -199.72% beat CEL-SCI Corp.'s return on equity of -266.61%.
Company Gross Margin Earnings Per Share Invested Capital BRTXBioRestorative Therapies, Inc.-435.59% -$0.33 $2.2M CVMCEL-SCI Corp.-- -$1.36 $17M -
What do Analysts Say About BRTX or CVM?
BioRestorative Therapies, Inc. has a consensus price target of $13.00, signalling upside risk potential of 1081.82%. On the other hand CEL-SCI Corp. has an analysts' consensus of $42.50 which suggests that it could grow by 555.86%. Given that BioRestorative Therapies, Inc. has higher upside potential than CEL-SCI Corp., analysts believe BioRestorative Therapies, Inc. is more attractive than CEL-SCI Corp..
Company Buy Ratings Hold Ratings Sell Ratings BRTXBioRestorative Therapies, Inc.1 0 0 CVMCEL-SCI Corp.1 0 0 -
Is BRTX or CVM More Risky?
BioRestorative Therapies, Inc. has a beta of 0.082, which suggesting that the stock is 91.819% less volatile than S&P 500. In comparison CEL-SCI Corp. has a beta of 0.487, suggesting its less volatile than the S&P 500 by 51.259%.
-
Which is a Better Dividend Stock BRTX or CVM?
BioRestorative Therapies, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CEL-SCI Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioRestorative Therapies, Inc. pays -- of its earnings as a dividend. CEL-SCI Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BRTX or CVM?
BioRestorative Therapies, Inc. quarterly revenues are $11.8K, which are larger than CEL-SCI Corp. quarterly revenues of --. BioRestorative Therapies, Inc.'s net income of -$3M is higher than CEL-SCI Corp.'s net income of -$5.7M. Notably, BioRestorative Therapies, Inc.'s price-to-earnings ratio is -- while CEL-SCI Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioRestorative Therapies, Inc. is 23.77x versus -- for CEL-SCI Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BRTXBioRestorative Therapies, Inc.23.77x -- $11.8K -$3M CVMCEL-SCI Corp.-- -- -- -$5.7M
-
Which has Higher Returns BRTX or IGC?
IGC Pharma, Inc. has a net margin of -25748.31% compared to BioRestorative Therapies, Inc.'s net margin of -953.4%. BioRestorative Therapies, Inc.'s return on equity of -199.72% beat IGC Pharma, Inc.'s return on equity of -94.42%.
Company Gross Margin Earnings Per Share Invested Capital BRTXBioRestorative Therapies, Inc.-435.59% -$0.33 $2.2M IGCIGC Pharma, Inc.-3.14% -$0.02 $8.2M -
What do Analysts Say About BRTX or IGC?
BioRestorative Therapies, Inc. has a consensus price target of $13.00, signalling upside risk potential of 1081.82%. On the other hand IGC Pharma, Inc. has an analysts' consensus of $3.88 which suggests that it could grow by 1081.76%. Given that BioRestorative Therapies, Inc. has higher upside potential than IGC Pharma, Inc., analysts believe BioRestorative Therapies, Inc. is more attractive than IGC Pharma, Inc..
Company Buy Ratings Hold Ratings Sell Ratings BRTXBioRestorative Therapies, Inc.1 0 0 IGCIGC Pharma, Inc.2 0 0 -
Is BRTX or IGC More Risky?
BioRestorative Therapies, Inc. has a beta of 0.082, which suggesting that the stock is 91.819% less volatile than S&P 500. In comparison IGC Pharma, Inc. has a beta of 0.242, suggesting its less volatile than the S&P 500 by 75.839%.
-
Which is a Better Dividend Stock BRTX or IGC?
BioRestorative Therapies, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IGC Pharma, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioRestorative Therapies, Inc. pays -- of its earnings as a dividend. IGC Pharma, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BRTX or IGC?
BioRestorative Therapies, Inc. quarterly revenues are $11.8K, which are smaller than IGC Pharma, Inc. quarterly revenues of $191K. BioRestorative Therapies, Inc.'s net income of -$3M is lower than IGC Pharma, Inc.'s net income of -$1.8M. Notably, BioRestorative Therapies, Inc.'s price-to-earnings ratio is -- while IGC Pharma, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioRestorative Therapies, Inc. is 23.77x versus 24.61x for IGC Pharma, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BRTXBioRestorative Therapies, Inc.23.77x -- $11.8K -$3M IGCIGC Pharma, Inc.24.61x -- $191K -$1.8M
-
Which has Higher Returns BRTX or TOI?
The Oncology Institute, Inc. has a net margin of -25748.31% compared to BioRestorative Therapies, Inc.'s net margin of -10.08%. BioRestorative Therapies, Inc.'s return on equity of -199.72% beat The Oncology Institute, Inc.'s return on equity of -9486.64%.
Company Gross Margin Earnings Per Share Invested Capital BRTXBioRestorative Therapies, Inc.-435.59% -$0.33 $2.2M TOIThe Oncology Institute, Inc.12.59% -$0.14 $91.3M -
What do Analysts Say About BRTX or TOI?
BioRestorative Therapies, Inc. has a consensus price target of $13.00, signalling upside risk potential of 1081.82%. On the other hand The Oncology Institute, Inc. has an analysts' consensus of $6.50 which suggests that it could grow by 85.71%. Given that BioRestorative Therapies, Inc. has higher upside potential than The Oncology Institute, Inc., analysts believe BioRestorative Therapies, Inc. is more attractive than The Oncology Institute, Inc..
Company Buy Ratings Hold Ratings Sell Ratings BRTXBioRestorative Therapies, Inc.1 0 0 TOIThe Oncology Institute, Inc.3 0 0 -
Is BRTX or TOI More Risky?
BioRestorative Therapies, Inc. has a beta of 0.082, which suggesting that the stock is 91.819% less volatile than S&P 500. In comparison The Oncology Institute, Inc. has a beta of 0.162, suggesting its less volatile than the S&P 500 by 83.817%.
-
Which is a Better Dividend Stock BRTX or TOI?
BioRestorative Therapies, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. The Oncology Institute, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioRestorative Therapies, Inc. pays -- of its earnings as a dividend. The Oncology Institute, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BRTX or TOI?
BioRestorative Therapies, Inc. quarterly revenues are $11.8K, which are smaller than The Oncology Institute, Inc. quarterly revenues of $136.6M. BioRestorative Therapies, Inc.'s net income of -$3M is higher than The Oncology Institute, Inc.'s net income of -$13.8M. Notably, BioRestorative Therapies, Inc.'s price-to-earnings ratio is -- while The Oncology Institute, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioRestorative Therapies, Inc. is 23.77x versus 0.65x for The Oncology Institute, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BRTXBioRestorative Therapies, Inc.23.77x -- $11.8K -$3M TOIThe Oncology Institute, Inc.0.65x -- $136.6M -$13.8M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did Netflix Buy Warner Bros?
Following a bidding war, Netflix (NASDAQ:NFLX) has announced its intention…
Why Did SoFi Stock Drop?
Fintech platform SoFi (NASDAQ:SOFI) has stumbled in recent days, selling…
Stock Ideas
Buy
51
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
58
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
59
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
61
PLAB alert for Dec 12
Photronics, Inc. [PLAB] is up 6.18% over the past day.
Buy
77
DHIL alert for Dec 12
Diamond Hill Investment Group, Inc. [DHIL] is up 44.46% over the past day.
Buy
100
WRBY alert for Dec 12
Warby Parker, Inc. [WRBY] is up 2.23% over the past day.
